SCD — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL242626	1.00	19/20
SCHEMBL242770	1.00	19/20
SCHEMBL243527	1.00	19/20
SCHEMBL243761	1.00	19/20
SCHEMBL243821	1.00	19/20
SCHEMBL244492	1.00	19/20
SCHEMBL244557	1.00	19/20
SCHEMBL242621	0.98	19/20
SCHEMBL241505	0.95	19/20
SCHEMBL242655	0.95	19/20
SCHEMBL244281	0.85	19/20
SCHEMBL244374	0.84	19/20
SCHEMBL243603	0.84	19/20
SCHEMBL241070	0.80	19/20
SCHEMBL243619	0.80	19/20
SCHEMBL242789	0.76	19/20
SCHEMBL243604	0.75	19/20
SCHEMBL240437	0.73	19/20
SCHEMBL244533	0.73	19/20
SCHEMBL243367	0.73	19/20

Clinical trials — most relevant to SCD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
The Sleep, Liver Evaluation and Effective Pressure Study	PHASE2	COMPLETED
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver	PHASE2	COMPLETED
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease	EARLY_PHASE1	COMPLETED
Stearoyl-CoA Desaturase and Energy Metabolism in Humans	nan	COMPLETED
Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids	nan	UNKNOWN
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction	nan	UNKNOWN
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes	nan	COMPLETED
Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Activity of Essential Fatty Acid Elongation/Desaturation Pathway During Early Life in Human Infants, In Vivo	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
De Novo Lipogenesis in Severity of NAFLD	nan	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome	nan	COMPLETED
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
The Effects of Milk Protein Versus Soy Protein on Essential Omega-3 Fatty Acid Metabolism	nan	ACTIVE_NOT_RECRUITING
Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV	nan	NOT_YET_RECRUITING
Hepatic Glycogen and Fat Oxidation	nan	COMPLETED
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations	nan	UNKNOWN
Determinants of Liver Fat Composition	nan	COMPLETED
Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SCD binder may also engage these)

Protein	Name	Similarity
Q6T707	—	1.000	Q6T707 →
P07308	—	1.000	P07308 →
O02858	—	1.000	O02858 →
P13516	—	1.000	P13516 →
Q9TT94	—	1.000	Q9TT94 →
Q95MI7	—	1.000	Q95MI7 →
Q99PL7	—	1.000	Q99PL7 →
Q6P7B9	—	1.000	Q6P7B9 →
O62849	—	1.000	O62849 →
P13011	—	1.000	P13011 →
G5EGN2	—	1.000	G5EGN2 →
Q64420	—	1.000	Q64420 →
O44390	—	0.998	O44390 →
Q75PL7	—	0.998	Q75PL7 →
Q8ISS3	—	0.997	Q8ISS3 →
B7SB92	—	0.997	B7SB92 →
Q6US81	—	0.996	Q6US81 →
Q9BH41	—	0.996	Q9BH41 →
G5EGH6	—	0.995	G5EGH6 →
G5ED44	—	0.995	G5ED44 →
Q2KIA4	—	0.994	Q2KIA4 →
B7SB91	—	0.994	B7SB91 →
SCD5	Stearoyl-CoA desaturase 5	0.993	landscape →
P48618	—	0.993	P48618 →
Q92038	—	0.991	Q92038 →
O94523	—	0.991	O94523 →
P48623	—	0.991	P48623 →
O59715	—	0.990	O59715 →
Q8NKG9	—	0.989	Q8NKG9 →
P21147	—	0.989	P21147 →